SS-31 25MG

SS-31 25MG

$156.00

SS-31 enhances mitochondrial function by reducing oxidative stress and inflammation. It’s being studied for its potential benefits in diseases like Alzheimer’s and heart disease.

72 in stock (can be backordered)

Product Usage: This product is designated as a "Novelty Peptide" and is intended solely for specialized applications in controlled settings. It is not intended for any specific biological, therapeutic, or diagnostic use. All information provided on this website is for informational and educational purposes only and should not be construed as guidance for any particular application or usage.

download

SS-31 (also known as elamipretide, MTP-131, or Bendavia) is a synthetic tetrapeptide that specifically targets mitochondria. It belongs to the Szeto-Schiller (SS) family of peptides designed to improve mitochondrial function. SS-31 has gained significant attention in research for its potential therapeutic applications in various conditions associated with mitochondrial dysfunction, including heart failure, kidney disease, neurodegenerative disorders, and aging-related diseases.

Sequence: D-Arg-Dmt-Lys-Phe-NH2

Molecular Formula: C32H49N9O5

Molecular Weight:639.8 g/mol

CAS Number:736992-21-5

  1. Mitochondrial Targeting: SS-31 selectively accumulates in the inner mitochondrial membrane, with a concentration approximately 5000-fold higher than in the surrounding environment.
  2. Cardiolipin Interaction: SS-31 binds to cardiolipin, a key phospholipid in the inner mitochondrial membrane, helping to maintain mitochondrial cristae structure and promote the assembly of respiratory complexes into supercomplexes.
  3. Antioxidant Effects: Studies have shown that SS-31 reduces the production of reactive oxygen species (ROS) in mitochondria, protecting against oxidative stress.
  4. ATP Production: SS-31 has been demonstrated to improve mitochondrial function by increasing ATP production and oxygen consumption.
  5. Neuroprotection: Research indicates potential neuroprotective effects of SS-31 in models of various neurodegenerative diseases, including Alzheimer's and Parkinson's disease.

  1. Clinical Trials: Further human clinical trials are needed to evaluate the efficacy and safety of SS-31 in various conditions, particularly in heart failure, kidney disease, and neurodegenerative disorders.
  2. Mechanism of Action: Additional studies to fully elucidate the molecular mechanisms by which SS-31 exerts its diverse effects across different tissue types are required.
  3. Combination Therapies: Exploration of potential synergistic effects of SS-31 with other therapeutic agents could open new avenues for treatment in various medical fields.
  4. Long-term Safety: Extended studies are necessary to assess the long-term effects and safety profile of SS-31 administration in diverse patient populations.
  5. Optimal Dosing Regimens: Research into optimal delivery methods and dosing regimens for different conditions could enhance the therapeutic potential of SS-31.

  1. Szeto, H.H., et al. (2011). Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury. Journal of the American Society of Nephrology, 22(6), 1041-1052. [Online].
    Available: https://pubmed.ncbi.nlm.nih.gov/21546574/
  2. Zhao, K., et al. (2004). Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. Journal of Biological Chemistry, 279(33), 34682-34690. [Online].
    Available: https://pubmed.ncbi.nlm.nih.gov/15178689/
  3. Birk, A.V., et al. (2013). The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology, 24(8), 1250-1261. [Online].
    Available: https://pubmed.ncbi.nlm.nih.gov/23813215/
  4. Zhao, W., et al. (2019). Mitochondria-targeted antioxidant peptide SS-31 protects cultured human lens epithelial cells against oxidative stress. Current Eye Research, 44(10), 1123-1132. [Online].
    Available: https://pubmed.ncbi.nlm.nih.gov/31169418/
  5. Escribano-Lopez, I., et al. (2019). The mitochondrial antioxidant SS-31 modulates oxidative stress, endoplasmic reticulum stress, and autophagy in type 2 diabetes. Journal of Clinical Medicine, 8(9), 1322. [Online].
    Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6780723/
SS-31 represents a promising avenue for mitochondrial-targeted therapy in various diseases associated with mitochondrial dysfunction. As research progresses, SS-31 may offer new treatment options for conditions ranging from heart failure to neurodegenerative disorders. However, as with all novel therapeutic agents, it is important to approach SS-31 with caution, and its potential benefits and risks require ongoing evaluation through long-term clinical studies and further research.